About Myrexis (OTCMKTS:MYRX)
Myrexis, Inc. focuses on identifying, evaluating, and making financial investments in life sciences assets. The company was formerly known as Myriad Pharmaceuticals, Inc. and changed its name to Myrexis, Inc. in July 2010. Myrexis, Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:MYRX
CUSIPN/A
Phone801-214-7800
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares34,480,000
Myrexis (OTCMKTS:MYRX) Frequently Asked Questions
What is Myrexis' stock symbol?
Myrexis trades on the OTCMKTS under the ticker symbol "MYRX."
Who are some of Myrexis' key competitors?
Some companies that are related to Myrexis include Anthera Pharmaceuticals (ANTH), Stellar Biotechnologies (SBOT), Bioblast Pharma (ORPN), Biostar Pharmaceuticals (BSPM), Peak Pharmaceuticals (PKPH), Boston Therapeutics (BTHE), Heat Biologics (HTBX), Apricus Biosciences (APRI), Cotinga Pharmaceuticals (COTQF), Praxsyn (PXYN), Parnell Pharmaceuticals (PARNF), Amarillo Biosciences (AMAR), Orexigen Therapeutics (OREX), Integrated BioPharma (INBP) and RespireRx (RSPI).
Who are Myrexis' key executives?
Myrexis' management team includes the folowing people:
- Mr. Jonathan M. Couchman CFA, Chairman, CEO, Pres, CFO and Principal Accounting Officer (Age 48)
Has Myrexis been receiving favorable news coverage?
Media headlines about MYRX stock have trended somewhat positive on Monday, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Myrexis earned a news impact score of 0.16 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.54 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Myrexis?
Shares of MYRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myrexis' stock price today?
One share of MYRX stock can currently be purchased for approximately $0.0495.
How big of a company is Myrexis?
Myrexis has a market capitalization of $1.97 million.
How can I contact Myrexis?
Myrexis' mailing address is C/O XSTELOS HOLDINGS INC. 630 FIFTH AVENUE SUITE 2260, NEW YORK NY, 10020. The biopharmaceutical company can be reached via phone at 801-214-7800 or via email at [email protected]
MarketBeat Community Rating for Myrexis (MYRX)
MarketBeat's community ratings are surveys of what our community members think about Myrexis and other stocks. Vote "Outperform" if you believe MYRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Myrexis (OTCMKTS:MYRX) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
(Data available from 4/23/2016 forward)
Myrexis (OTCMKTS:MYRX) Earnings History and Estimates Chart
Myrexis (OTCMKTS MYRX) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2013 | Q3 2013 | | ($0.11) | | | View | N/A |  |
| 9/13/2012 | Q4 2012 | | ($0.16) | | | View | N/A | |
| 5/10/2012 | Q3 2012 | | ($0.27) | | | View | N/A | |
| 2/9/2012 | Q2 2012 | | ($0.29) | | | View | N/A | |
| 11/9/2011 | Q1 2012 | ($0.27) | ($0.33) | | | View | N/A | |
| 9/8/2011 | Q4 2011 | ($0.35) | ($0.31) | | | View | N/A | |
| 5/10/2011 | Q3 2011 | ($0.55) | ($0.50) | | | View | N/A | |
| 2/9/2011 | Q2 2011 | ($0.45) | ($0.31) | | | View | N/A | |
| 11/9/2010 | Q1 2011 | ($0.51) | ($0.40) | | | View | N/A | |
| 9/9/2010 | Q4 2010 | ($0.51) | ($0.31) | | | View | N/A | |
| 5/17/2010 | Q3 2010 | ($0.55) | ($0.56) | | | View | N/A | |
| 2/16/2010 | Q2 2010 | ($0.45) | ($0.60) | | | View | N/A | |
| 11/12/2009 | Q1 2010 | | ($0.44) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Myrexis (OTCMKTS:MYRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 1/25/2013 | special | $2.86 | | 2/19/2013 | 2/4/2013 | 2/15/2013 |
(Data available from 1/1/2013 forward)
Myrexis (OTCMKTS MYRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 0.29%
Myrexis (OTCMKTS MYRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Myrexis (OTCMKTS MYRX) News Headlines
| Source: |
|
No headlines for this company have been tracked by MarketBeat.com
Myrexis (OTCMKTS:MYRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Myrexis (OTCMKTS:MYRX) Income Statement, Balance Sheet and Cash Flow Statement
Myrexis (OTCMKTS MYRX) Stock Chart for Monday, April, 23, 2018
Loading chart…
